Clinical Trial Update: Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 clinical trial (SYNSTAR01) evaluating SYS6010 versus platinum-based chemotherapy in EGFR-mutated NSCLC. The trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SYS6010

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: EGFR-mutated Locally Advanced or Metastatic NSCLC | Phase 3 | Status: RECRUITING